| Outcome Measures: |
Primary: HbA1c Change From Baseline at Week 24, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication., Baseline and week 24 | Secondary: HbA1c Change From Baseline at Week 6, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication., Baseline and week 6|HbA1c Change From Baseline at Week 12, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication., Baseline and week 12|HbA1c Change From Baseline at Week 18, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication., Baseline and week 18|FPG Change From Baseline at Week 24, This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication., Baseline and week 24|FPG Change From Baseline at Week 6, This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication., Baseline and week 6|FPG Change From Baseline at Week 12, This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication., Baseline and week 12|FPG Change From Baseline at Week 18, This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication., Baseline and week 18|Percentage of Patients With HbA1c <7.0% at Week 24, The percentage of patients with an HbA1c value below 7.0% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \>= 7.0%. Only patients with baseline HbA1c \>= 7%, Baseline and week 24|Percentage of Patients With HbA1c<7.0% at Week 24, The percentage of patients with an HbA1c value below 7.0% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \>= 7.0%., Baseline and week 24|Percentage of Patients With HbA1c <6.5% at Week 24, The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \>= 6.5%. Only patients with baseline HbA1c \>= 6.5%., Baseline and week 24|Percentage of Patients With HbA1c<6.5% at Week 24, The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \>= 6.5%., Baseline and week 24|Percentage of Patients With HbA1c Lowering by 0.5% at Week 24, The percentage of patients with an HbA1c reduction from baseline \>= 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%., Baseline and week 24|Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24, This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline PPG and previous anti-diabetic medication., Baseline and week 24
|
| Locations: |
1218.16.38605 Boehringer Ingelheim Investigational Site, Krapinske Toplice, Croatia|1218.16.38604 Boehringer Ingelheim Investigational Site, Slavonski Brod, Croatia|1218.16.91009 Boehringer Ingelheim Investigational Site, Andhra Pradesh, India|1218.16.91002 Boehringer Ingelheim Investigational Site, Bangalore, India|1218.16.91005 Boehringer Ingelheim Investigational Site, Bangalore, India|1218.16.91014 Boehringer Ingelheim Investigational Site, Chennai, India|1218.16.91013 Boehringer Ingelheim Investigational Site, Ghaziabad, India|1218.16.91010 Boehringer Ingelheim Investigational Site, Hyderabad, India|1218.16.91006 Boehringer Ingelheim Investigational Site, Jaipur, India|1218.16.91011 Boehringer Ingelheim Investigational Site, Maharashtra, India|1218.16.91008 Boehringer Ingelheim Investigational Site, Mangalore, India|1218.16.91007 Boehringer Ingelheim Investigational Site, Manipal, India|1218.16.91004 Boehringer Ingelheim Investigational Site, Mumbai, India|1218.16.91003 Boehringer Ingelheim Investigational Site, Nasik, India|1218.16.91012 Boehringer Ingelheim Investigational Site, Tamilnadu, India|1218.16.91001 Boehringer Ingelheim Investigational Site, Trivandrum, Kerala, India|1218.16.97267 Boehringer Ingelheim Investigational Site, Givataim, Israel|1218.16.97263 Boehringer Ingelheim Investigational Site, Haifa, Israel|1218.16.97265 Boehringer Ingelheim Investigational Site, Holon, Israel|1218.16.97261 Boehringer Ingelheim Investigational Site, Jerusalem, Israel|1218.16.97262 Boehringer Ingelheim Investigational Site, Nahariya, Israel|1218.16.97266 Boehringer Ingelheim Investigational Site, Safed, Israel|1218.16.39004 Boehringer Ingelheim Investigational Site, Catanzaro, Italy|1218.16.39008 Boehringer Ingelheim Investigational Site, Genova, Italy|1218.16.39002 Boehringer Ingelheim Investigational Site, Milano, Italy|1218.16.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|1218.16.39006 Boehringer Ingelheim Investigational Site, Roma, Italy|1218.16.60006 Boehringer Ingelheim Investigational Site, Alor Star, Malaysia|1218.16.60003 Boehringer Ingelheim Investigational Site, Kelantan Kota Bahru, Malaysia|1218.16.60001 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia|1218.16.60002 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia|1218.16.60004 Boehringer Ingelheim Investigational Site, Perak, Malaysia|1218.16.60005 Boehringer Ingelheim Investigational Site, Perak, Malaysia|1218.16.60007 Boehringer Ingelheim Investigational Site, Pulau Pinang, Malaysia|1218.16.31009 Boehringer Ingelheim Investigational Site, Andijk, Netherlands|1218.16.31024 Boehringer Ingelheim Investigational Site, Castricum, Netherlands|1218.16.31006 Boehringer Ingelheim Investigational Site, Deurne, Netherlands|1218.16.31001 Boehringer Ingelheim Investigational Site, Ewijk, Netherlands|1218.16.31010 Boehringer Ingelheim Investigational Site, Losser, Netherlands|1218.16.31003 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|1218.16.31021 Boehringer Ingelheim Investigational Site, Poortvliet, Netherlands|1218.16.31004 Boehringer Ingelheim Investigational Site, Rijswijk, Netherlands|1218.16.31008 Boehringer Ingelheim Investigational Site, Roelofarendsveen, Netherlands|1218.16.31002 Boehringer Ingelheim Investigational Site, Wildervank, Netherlands|1218.16.48603 Boehringer Ingelheim Investigational Site, Lublin, Poland|1218.16.48601 Boehringer Ingelheim Investigational Site, Warsaw, Poland|1218.16.48604 Boehringer Ingelheim Investigational Site, Zabrze, Poland|1218.16.40604 Boehringer Ingelheim Investigational Site, Brasov, Romania|1218.16.40603 Boehringer Ingelheim Investigational Site, Galati, Romania|1218.16.42103 Boehringer Ingelheim Investigational Site, Banska Bystrica, Slovakia|1218.16.42102 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.16.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.16.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.16.42101 Boehringer Ingelheim Investigational Site, Nove Mesto nad Vahom, Slovakia|1218.16.42106 Boehringer Ingelheim Investigational Site, Samorin, Slovakia|1218.16.66001 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|1218.16.66002 Boehringer Ingelheim Investigational Site, Khon Kaen, Thailand|1218.16.38011 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|1218.16.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|1218.16.38004 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1218.16.38010 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1218.16.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.16.38005 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.16.38008 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.16.38009 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.16.38012 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.16.38003 Boehringer Ingelheim Investigational Site, Lvov, Ukraine|1218.16.38006 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|1218.16.38007 Boehringer Ingelheim Investigational Site, Zaporizhzhya, Ukraine
|
